by
This new blood-drawing device developed with the help of the Defense Advanced Research Projects Agency is easy for anyone to use, according to its manufacturer, Tasso Inc. (Tasso Inc.)
Medics jabbing troops with needles for blood tests in remote locations may become a thing of the past thanks to some new technology.
A blood-drawing and testing device, developed with the help of the Defense Advanced Research Projects Agency, is easy for anyone to use, according to its manufacturer.
Seattle-based telemedicine company Tasso developed the blood-tester after winning a $150,000 DARPA grant in 2013, according to company CEO Ben Casavant.
To use the Tasso Device, a patient places it on their arm and pushes a large red button that activates a needle. Meanwhile, a vacuum draws blood to the skin’s surface to be collected in a tube, he said in a telephone interview Friday.
HJF Receives Patent for Potential Treatment for Nerve Agent Exposure
News provided by
Share this article
Share this article
BETHESDA, Md., May 11, 2021 /PRNewswire/ The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) received notice of allowance for a patent from the United States Patent Office (USPO) for a medical countermeasure to organophosphate (OP) nerve agent exposure. Among OP nerve agents is the deadly chemical weapon, Sarin. Led by Maria F. Braga, DDS, PhD, a professor of Anatomy, Physiology and Genetics, and Psychiatry in the in the School of Medicine at the Uniformed Services University of the Health Sciences (USU), researchers identified a neuroprotective combination therapy that is effective against OP exposure. The therapy was shown to be effective even with delayed use following nerve agent exposure. This innovation was patented by the USU/HJF Joint Office of Technology Transfer.
The experiments revealed that in open air, simulants decayed 10 to 1,000 times faster than in laboratory settings. These data indicate that laboratory tests underestimate the rate of agent decay that occurs outdoors, and on their own, laboratory tests are not sufficient in understanding the decay process outdoors.
To learn how biological threat agents decay upon interacting with variables in the open air, the Defense Threat Reduction Agency’s Chemical and Biological Technologies Department (DTRA CB) developed a new, state-of-the-art test apparatus, the Captive Aerosol Growth and Evolution System (CAGES).
“Due to various challenges posed by outdoor testing, it was generally assumed by scientists that biological threat agents aged and decayed at similar rates indoors as they did outdoors. Our goal was to test this theory,” said Richard Mathieson, Science & Technology Manager, DTRA CB.
Carbon Nanotube Membranes can Enable Rapid Dialysis Processes
Written by AZoNanoJan 8 2021
Scientists from the Lawrence Livermore National Laboratory have found that ultra-rapid dialysis processes could be achieved by carbon nanotube membrane pores, resulting in considerably reduced treatment time for patients undergoing hemodialysis.
Artistic rendering of fast ion permeation inside single-walled carbon nanotubes. Small ions such as potassium, chloride, and sodium permeate through the inner volume of nanometer-wide carbon nanotubes at rates that surpass diffusion in bulk water by an order of magnitude. Image Credit: Francesco Fornasiero/Lawrence Livermore National Laboratory.
In manmade and biological processes, the potential to isolate molecular components in complex solutions is very important. One way to do this is to apply a concentration gradient across a porous membrane. This method fuels molecules or ions that are smaller in comparison to the pore diameters from one side o